Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1651 1699
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17512794 | TREATMENT OF CARDIAC DISORDERS BY BLOCKING SK4 POTASSIUM CHANNEL | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 16307298 | Method and Composition For Reducing Pathogens in Pet Food Using Lactic Acid Bacteria | Final Rejection | Texas Tech University System |
| 18120319 | COMPOSITIONS INCLUDING ENDOPHYTES FOR IMPROVING PLANT NUTRITION, GROWTH,AND PERFORMANCE AND METHODS OF USING THE SAME | Non-Final OA | University of Washington |
| 18541764 | DEVICES AND METHODS FOR DETECTING PANCREATIC LIPASE | Non-Final OA | IDEXX LABORATORIES, INC. |
| 17795203 | LAUNDRY DETERGENT PRODUCT | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18791967 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | Non-Final OA | GenMont Biotech Incorporation |
| 18619589 | CANCER RISK ASSESSMENT | Non-Final OA | Micromass UK Limited |
| 18714344 | USES OF COMPOSITIONS COMPRISING A PREBIOTIC COMPONENT | Non-Final OA | Mead Johnson Nutrition Company |
| 18551160 | Enzyme Immobilization Carrier and Preparation Method thereof, Immobilized Enzyme and Preparation Method thereof | Non-Final OA | Asymchem Laboratories (Tianjin) Co., Ltd. |
| 18534572 | ANTIVIRAL ANIMAL FEED ADDITIVE | Non-Final OA | Changde Jizhi Biological Technology Co., Ltd |
| 18554464 | METHOD FOR PRODUCING TAGATOSE FROM BIOMIMETIC SILICON MINERALIZED MICROCAPSULE IMMOBILIZED MULTI-ENZYME | Non-Final OA | Tianjin Yeahe Biotechnology Co., Ltd |
| 17905736 | COMPOSITIONS AND METHODS FOR PRODUCTION OF GLUCOSE OXIDATION PRODUCTS | Final Rejection | Solugen, Inc. |
| 18396458 | SUPEROXIDE DISMUTASE COMPOSITIONS AND METHODS | Final Rejection | Blue Sky Innovation, LLC |
| 17978019 | SUPEROXIDE DISMUTASE COMPOSITIONS AND METHODS | Non-Final OA | Blue Sky Innovation, LLC |
| 18252995 | WOUND HEALING | Non-Final OA | GRIFOLS WORLDWIDE OPERATIONS LIMITED |
| 18254449 | DESIGNED BACTERIAL COMPOSITIONS FOR TREATING GRAFT-VERSUS-HOST-DISEASE | Non-Final OA | Seres Therapeutics, Inc. |
| 18228761 | Catechol Nanoparticle, Catechol Protein Nanoparticle, and Preparation Method and Use Thereof | Non-Final OA | Shihezi University |
| 18563277 | ALKALINE PHOSPHATASE-BASED TREATMENTS OF CELIAC DISEASE | Non-Final OA | Theriva Biologics, Inc. |
| 18277572 | COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMS | Non-Final OA | VEDANTA BIOSCIENCES, INC. |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | Non-Final OA | Children's Medical Center Corporation |
| 18221529 | TOPICAL COMPOSITION | Non-Final OA | LILIGER LTD |
| 18259576 | METHODS OF CANCER TREATMENT BY INTRATUMORAL INJECTION OF MUTANT COLLAGENASE | Final Rejection | REJUVEN DERMACEUTICAL CO., LTD. |
| 18265076 | ELEVATION OF GLYCOSAMINOGLYCANS IN SUBJECTS WITHOUT MUCOPOLYSACCHARIDOSIS | Non-Final OA | THE NEMOURS FOUNDATION |
| 18248648 | COMPOSITION FOR PREVENTING OR TREATING NEUROMUSCULAR DISEASE, COMPRISING PRMT1 PROTEIN OR GENE ENCODING SAME | Final Rejection | ANIMUSCURE INC. |
| 18041493 | A DISINTEGRIN AND METALLOPROTEINASE WITH A THROMBOSPONDIN TYPE I MOTIF, MEMBER 13 (ADAMTS-13) MUTANTS, COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | Final Rejection | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | Non-Final OA | Ipsen Biopharm Limited |
| 17759674 | TREATMENT OF SKIN CONDITIONS | Final Rejection | IPSEN BIOPHARM LIMITED |
| 18092980 | Fruit and Vegetable-Based Fermentate Compositions and Methods of Making and Using the Same | Non-Final OA | Third Wave Bioactives, LLC |
| 17788674 | MICROBIOME OPTIMIZATION | Final Rejection | GLYCIOME, LLC |
| 17756908 | NEW STRAINS OF LACTIC ACID BACTERIA, FOOD COMPOSITION COMPRISING THEM, PREPARATION OF SUCH COMPOSITION | Final Rejection | CELERY S.R.L. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy